Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults

NCT00621153 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00621153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00621153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
February 29, 2008
Completion date
March 31, 2009
Enrollment
214 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii hypertension